Feedback / Questions
Ampligen (rintatolimod) - AIM ImmunoTech
https://www.globenewswire.com/news-release/2026/02/05/3233016/0/en/AIM-ImmunoTech-Reports-Positive-Year-End-Interim-Clinical-Progress-from-Phase-2-Study-Evaluating-Ampligen-rintatolimod-in-Combination-with-AstraZeneca-s-Imfinzi-durvalumab-for-the-.html
Feb 5, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next